Comparison 11. Triple therapy with cyclophosphamide (CPA), mycophenolate mofetil (MMF) or leflunomide (LEF).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Short‐term response (remission)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
1.1 MMF versus CPA	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.2 LEF versus MMF	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.3 LEF versus CPA	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2 Long‐term response (remission at 12 months)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
2.1 MMF versus CPA	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2.2 LEF versus MMF	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2.3 LEF versus CPA	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]